These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 18479280

  • 1. Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting.
    Goodall G, Jendle JH, Valentine WJ, Munro V, Brandt AB, Ray JA, Roze S, Foos V, Palmer AJ.
    Int J Clin Pract; 2008 Jun; 62(6):869-76. PubMed ID: 18479280
    [Abstract] [Full Text] [Related]

  • 2. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.
    Ray JA, Valentine WJ, Roze S, Nicklasson L, Cobden D, Raskin P, Garber A, Palmer AJ.
    Diabetes Obes Metab; 2007 Jan; 9(1):103-13. PubMed ID: 17199725
    [Abstract] [Full Text] [Related]

  • 3. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.
    Valentine WJ, Palmer AJ, Lammert M, Nicklasson L, Foos V, Roze S.
    Curr Med Res Opin; 2005 Dec; 21(12):2063-71. PubMed ID: 16368057
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China.
    Palmer JL, Beaudet A, White J, Plun-Favreau J, Smith-Palmer J.
    Adv Ther; 2010 Nov; 27(11):814-27. PubMed ID: 21061114
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
    Lee KH, Seo SJ, Smith-Palmer J, Palmer JL, White J, Valentine WJ.
    Value Health; 2009 Nov; 12 Suppl 3():S55-61. PubMed ID: 20586983
    [Abstract] [Full Text] [Related]

  • 6. Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.
    Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P, Valentine WJ.
    Int J Clin Pharmacol Ther; 2009 Aug; 47(8):501-15. PubMed ID: 19640359
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting.
    Palmer JL, Knudsen MS, Aagren M, Thomsen TL.
    J Med Econ; 2010 Aug; 13(2):212-20. PubMed ID: 20350145
    [Abstract] [Full Text] [Related]

  • 8. Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US.
    Dempsey M, Mocarski M, Langer J, Hunt B.
    J Med Econ; 2018 Nov; 21(11):1110-1118. PubMed ID: 30114954
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
    Brändle M, Azoulay M, Greiner RA.
    Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.
    Brändle M, Azoulay M, Greiner RA.
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):203-20. PubMed ID: 17474539
    [Abstract] [Full Text] [Related]

  • 11. Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.
    Tunis SL, Sauriol L, Minshall ME.
    Appl Health Econ Health Policy; 2010 Apr; 8(4):267-80. PubMed ID: 20578781
    [Abstract] [Full Text] [Related]

  • 12. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ.
    Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
    [Abstract] [Full Text] [Related]

  • 13. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
    Ligthelm RJ, Gylvin T, DeLuzio T, Raskin P.
    Endocr Pract; 2011 Mar; 17(1):41-50. PubMed ID: 20713345
    [Abstract] [Full Text] [Related]

  • 14. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes.
    Valentine WJ, Goodall G, Aagren M, Nielsen S, Palmer AJ, Erny-Albrecht K.
    Adv Ther; 2008 Jun; 25(6):567-84. PubMed ID: 18568451
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.
    Palmer JL, Goodall G, Nielsen S, Kotchie RW, Valentine WJ, Palmer AJ, Roze S.
    Curr Med Res Opin; 2008 May; 24(5):1417-28. PubMed ID: 18400145
    [Abstract] [Full Text] [Related]

  • 16. Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective.
    Jendle J, Ericsson Å, Ekman B, Sjöberg S, Gundgaard J, da Rocha Fernandes J, Mårdby AC, Hunt B, Malkin SJP, Thunander M.
    J Med Econ; 2020 Nov; 23(11):1311-1320. PubMed ID: 32746676
    [Abstract] [Full Text] [Related]

  • 17. Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes.
    Valentine WJ, Pollock RF, Plun-Favreau J, White J.
    Curr Med Res Opin; 2010 Jun; 26(6):1399-412. PubMed ID: 20387997
    [Abstract] [Full Text] [Related]

  • 18. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
    Gupta V, Baabbad R, Hammerby E, Nikolajsen A, Shafie AA.
    J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
    Halimi S, Raskin P, Liebl A, Kawamori R, Fulcher G, Yan G.
    Clin Ther; 2005 Apr; 27 Suppl B():S57-74. PubMed ID: 16519038
    [Abstract] [Full Text] [Related]

  • 20. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.
    Ali M, White J, Lee CH, Palmer JL, Smith-Palmer J, Fakhoury W, Valentine WJ.
    J Med Econ; 2008 Apr; 11(4):651-70. PubMed ID: 19450074
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.